INTRODUCTION
Patients presenting with a mass lesion often undergo fine needle aspiration (FNA) as part of initial workup. In instances where patients present with metastatic disease, or in other scenarios where surgery is not indicated, FNA can 1) provide definitive evidence of a malignant process, 2) classify the malignancy based on cellular differentiation and/or site of origin, and 3) obtain material for targeted therapy testing (eg, immune checkpoint and tyrosine kinase inhibitors).
1,2 These 3 items allow the clinical team to proceed with the most appropriate treatment for the patient's malignancy. In instances in which a patient has no history of cancer and presents with a solitary lesion in an organ, under most circumstances the assumption should be that the lesion is primary to that organ. At some sites, consideration of metastatic disease is also warranted. Common sites for metastases investigated by FNA include lung, liver, bone and soft tissue, lymph node, and abdominopelvic masses without obvious relation to a specific organ. 3, 4 In situations where the patient has 1) a history of malignancy at another site, 2) a clinical or radiologic impression of metastatic disease, 3) a malignancy with cytomorphological features inconsistent with a primary neoplasm, or 4) a malignancy present at a site in which metastases are common, the sampled
Cancer Cytopathology August 2018 lesion should undergo additional testing as a possible cancer of unknown primary (CUP). The goals of CUP workup in cytologic specimens have evolved in the era of targeted testing. Unlike workup performed on larger resection specimens, cytologic material is limited and triage must balance several goals: 1) provide a sufficient level of tumor classification to the clinical team without spending unnecessary time and/or tissue if a more exact answer is not required; 2) limit the need for rebiopsy and/or unnecessary surgical excision; and 3) reserve sufficient material for targeted therapy testing, if needed (Fig. 1) . The investigating pathologist must maintain reasonable expectations and become neither overzealous in a search for an exact conclusion nor disappointed if a specific diagnosis is not achieved. Discussion with the treating physician while the workup is ongoing is useful, because it provides reassurance that the case has not been forgotten, allows earlier patient triage, and can inform the pathologist of an appropriate point to discontinue further workup. Upon being notified that the lesion is a CUP, the clinical team may be able to provide additional details to narrow the initial investigation, given the likelihood that they will have been conducting a clinical CUP workup in parallel. 5 Ancillary testing for CUP traditionally involves the use of immunoperoxidase (IPOX) staining performed on cell block, core biopsy material, or unstained smears. In desperate situations, Papanicolaou-stained slides can be destained and used for IPOX. [6] [7] [8] Cytomorphology and clinicoradiologic impression are required for an efficient IPOX workup; IPOX results should be interpreted with great caution if they conflict with clinicoradiologic impression or the neoplasm's cytomorphology. Proper interpretation of IPOX requires an understanding of the staining pattern (eg, nuclear, cytoplasmic, membranous, etc) of each marker. Furthermore, consideration of specimen adequacy is imperative, especially with cytologic material. Marker expression may be heterogeneous within a tumor, and FNA procedures can access only a limited area of the tumor. It is therefore reasonable to conclude that in some cases, marker expression in a biopsy sample may not be representative of the entire tumor. Care must also be taken in antibody selection. Some antibodies are specific to certain sites of origin, whereas others are specific to differentiation; the two should not be confused. For instance, an adenocarcinoma with squamous differentiation may stain positively for squamous markers such as p40. 9 The sensitivity and specificity of each antibody clone varies, and if questions arise, it may be necessary to confirm with the laboratory which specific clone is being used in a given case. 10 Another factor in IPOX interpretation, especially in cases of poorly differentiated neoplasms, is loss of site-specific marker expression. Staining for these markers may be focal and/or weak in these tumors. Conversely, poorly differentiated tumors may also aberrantly express certain markers in a focal or weak fashion. When critical markers (such as pan-keratin) are negative, the IPOX-positive control slide should be reviewed.
USING CYTOMORPHOLOGIC PATTERNS AS A STARTING POINT
Certain cytomorphologic characteristics of a tumor can be useful to tailor the selection of a narrowed and precise initial immunohistochemical panel. This selective approach helps to preserve samples by avoiding unnecessary staining. For instance, a neoplasm that appears to form gland-like structures or has squamous differentiation can initially be assumed to be a carcinoma and would not Overview of ancillary studies involved in workup of cancer of unknown primary (CUP), beginning with onsite evaluation. Suspicion of a lymphoma or sarcoma allows for additional collection for flow cytometric or cytogenetic studies. Immunoperoxidase (IPOX) workup begins with a panel of immunostains with broad specificity and/or high sensitivity, with confirmation of a positive result using more specific markers. Depending on the circumstances, a definitive diagnosis may not be required before the remaining specimen is triaged to ancillary studies for targeted therapy (eg, lung-specific mutation panel or PD-L1 IPOX).
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require the initial use of pan-keratin markers. Some cytomorphologic features are strongly associated with certain tumor types; in these situations, the initial investigation may include a focused panel of confirmatory markers (Table 1) . Some important morphologic patterns to recognize include: epithelial fragments; neuroendocrine differentiation; "small round blue cell" morphology; and predominantly spindle-cell morphology (Fig. 2) . If no such clues are present, the tumor can be considered undifferentiated; these neoplasms typically consist of dispersed epithelioid cells.
Single/Dispersed Epithelioid Cells
Tumors with an undifferentiated cytomorphology lack any architectural clues to guide initial workup and appear as individual, dispersed cells. These dispersed cells may appear to cluster, but do not form true tissue fragments. The broad differential in such cases includes carcinoma, melanoma, lymphoma, and sarcoma. Without guiding architectural features, help must be sought at the cellular level. Lymphomas and other hematopoietic malignancies often contain recognizable cytomorphologic features. Some hematopoietic malignancies are composed of monotonous cells, whereas others are more Cancer Cytopathology August 2018 Figure 3 . Workup of an undifferentiated tumor, which begins with generalized markers CD45, pankeratin, and S-100 protein to screen for lymphoma, carcinoma, and melanoma, respectively. Sarcomas are also in the differential but lack a common antigen for screening purposes. When all 3 markers are negative, sarcomas and poorly differentiated carcinoma cannot be excluded, creating a dilemma of whether to pursue additional epithelial markers (eg, CAM5.2, p40) to establish a carcinoma or to pursue a possible sarcoma. In men, NKX3.1 is a sensitive and specific marker for prostate carcinoma. Note the differences in staining patterns: AE1/AE3, cytoplasmic; S-100 protein, nuclear and cytoplasmic; CD45, membranous; and TTF-1, nuclear. Nuclear stains are easier to interpret, especially in limited specimens, and have grown in favor.
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pleomorphic. Tumors demonstrating great pleomorphism include undifferentiated pleomorphic sarcoma and pleomorphic carcinoma. Of note, markers of differentiation are often lost in pleomorphic undifferentiated carcinomas and sarcomas. The first step in the workup of these dispersed epithelioid lesions is to try and establish a line of differentiation (Fig. 3 ). An initial IPOX panel should include a pan-keratin cocktail, such as AE1/AE3, as well as S-100 protein, a sensitive but nonspecific marker for melanoma. If lymphoma cannot be excluded morphologically, leukocyte common antigen (LCA/CD45) can be added (Fig. 4) .
Strong and diffuse staining for S-100 protein on the initial panel requires the subsequent exclusion of melanoma. Because melanomas do not uniformly express all markers of melanocytic differentiation, more than 1 marker should be tested (Fig. 5 ). Sox-10 is a nuclear stain demonstrated to be highly sensitive for metastatic melanoma. Cancer Cytopathology August 2018
broad number of entities-or have a high sensitivity for detection-should be employed, as opposed to focused markers, or markers that sacrifice sensitivity for specificity (Table 2) . [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] At least 1 unstained slide should be reserved for a pan-keratin in case the initial workup is negative, because this provides the chance to diagnose a poorly differentiated carcinoma before the material is exhausted. If the workup remains negative, a broader panel of markers may be used, unless the clinical team prefers to proceed with targeted therapy testing ( Figures  7-9 ). [23] [24] [25] [26] [27] [28] Mesenchymal neoplasms and proliferations with epithelioid morphology can be mistaken for carcinomas and initially elude a proper workup. [29] [30] [31] Neoplastic cells in such lesions may appear in fragments and/or as dispersed cells. If multiple keratin markers are negative and therefore carcinoma excluded, an additional panel of markers can help to identify mesenchymal lesions with epithelioid morphology (Table 3) . Certain differentiation markers are available, but many mesenchymal neoplasms cannot be characterized by IPOX alone and require additional ancillary tests for translocations or chromosomal alterations, always with clinical impression guiding test selection. Because rare epithelioid sarcomas (such as epithelioid hemangioendothelioma and epithelioid angiosarcoma) can also be focally positive for keratin, these entities should be considered with unusual clinical presentations in young patients or in neoplasms with unusual morphologies.
Spindle Cells and/or Stroma
The presence of predominantly spindle cells and/or matrix material suggests the possibility of a mesenchymal neoplasm. The workup should begin with a pan-keratin and S-100 protein to exclude sarcomatoid carcinoma, spindle cell melanoma, and other nonmesenchymal neoplasms with spindled morphology (medullary thyroid carcinoma, atypical carcinoid, salivary gland neoplasms) (Fig. 10 ). Although patients with metastatic mesenchymal neoplasms often have a known history, a primary mesenchymal neoplasm may be clinically concerning for a metastatic tumor. Ancillary studies should therefore be focused based on the presenting site in the case of a solitary mass. [32] [33] [34] [35] In the case of a widely metastatic tumor, common markers of differentiation can be employed but may not be helpful in making a specific diagnosis (Table 4 ). In most instances, patients with a metastatic mesenchymal tumor will have a known history; however, recurrences may demonstrate a dedifferentiated or higher-grade morphology. In many cases, FNA material may not be sufficient for a specific diagnosis, because definitive classification of bone and soft tissue tumors often requires a large enough biopsy to both evaluate architecture and allow for molecular testing.
Small Round Cells
"Small round cell neoplasms" demonstrate dispersed single cells with minimal cytoplasm. The term "small round cell neoplasms" arose from the appearance of these tumors on tissue sections stained with hematoxylin Cancer Cytopathology August 2018 and eosin. In cytologic preparations, the neoplastic cells from these tumors may be obviously larger than lymphocytes and may exhibit distinct pleomorphism, especially on slides stained with Diff-Quik. The workup of these neoplasms has been described extensively in the literature and is summarized in Table 5 (Fig. 11 ).
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Neuroendocrine Cells
Tumors with neuroendocrine differentiation exist along a broad morphologic spectrum, but ultimately are united by a shared and distinctive chromatin pattern. Neoplasms with neuroendocrine differentiation have speckled or "salt and pepper" chromatin, which is most readily identified on Pap-stained preparations. Tumor cells may exist singly dispersed, in loose clusters, or as tissue fragments. Additionally, tumor cells may form rosettes that mimic glandular formations and raise the possibility of adenocarcinoma. Whereas many neuroendocrine tumors have monotonous, bland-appearing epithelioid cells with smooth nuclear borders, some tumors exist as predominantly spindled cells; therefore, neuroendocrine neoplasms should be considered in the differential diagnosis of any spindle cell tumor with neuroendocrine-type chromatin. Highergrade neuroendocrine malignancies, such as neuroendocrine carcinomas, often display more pleomorphic cells in contrast with the monotonous cytology of lower-grade tumors. The identification of neuroendocrine differentiation may indicate a specific tumor diagnosis (such as medullary thyroid carcinoma) or simply indicate neuroendocrine differentiation that is not specific to a particular site (such as an adenocarcinoma with neuroendocrine differentiation). Confirmatory IPOX for neuroendocrine differentiation classically includes chromogranin and synaptophysin (Fig. 12 ). INSM1 is a newer nuclear marker with increased sensitivity and specificity, though it is often negative in parathyroid-derived tissues. 39 Subsequent IPOX can be used to more specifically classify neuroendocrine neoplasms (Table 6 and Fig. 13 ). 40 
UNUSUAL CYTOMORPHOLOGIES
For neoplasms with unusual features that do not follow the rules, begin by reassessing previously made assumptions and consider whether the lesion may be a nonneoplastic proliferative process (a "pseudotumor"), a benign neoplasm, or a primary and not metastatic malignancy (Fig. 14) . This may include consideration of entities such as nodular fasciitis, paraganglioma, gastrointestinal stromal tumor, and benign ectopic tissue rests.
41-44
PATIENTS WITH A HISTORY OF MALIGNANCY
When patients have a specific history of malignancy, markers specific for the previous malignancy should Cancer Cytopathology August 2018 be included in the initial workup. In addition, certain malignancies are associated with particular risk factors, such as treatment of a prior malignancy (eg, angiosarcoma following radiation therapy), environmental exposures (eg, cancer of the lung and bladder being associated with cigarette smoking), or a familial syndrome (eg, breast and ovarian cancer). [45] [46] [47] Furthermore, the morphology of the initial tumor does not necessarily predict that of a metastasis or recurrence, such as when prostatic adenocarcinoma transforms and returns as small cell carcinoma. 48 
EXFOLIATIVE CYTOLOGY
The investigation of CUP on exfoliative cytology specimens is more challenging than on FNA. Exfoliative specimens typically contain less overall cellularity, and lesional cells typically make up a smaller proportion of the overall sample when compared with FNA-obtained Cancer Cytopathology August 2018 material. Additional unstained preparations and/or cell block material can be made from any residual specimen to allow for the use of IPOX. Very focused IPOX panels must be used in such cases; for instance, GATA3 and NKX3.1 can be performed on a urinary tract specimen to determine whether malignant cells are of prostate (NKX3.1 positive and GATA3 negative) or urothelial (GATA3 positive and NKX3.1 negative) origin. 49 
SPECIAL STAINS
Traditional non-immunohistochemical stains remain useful in a CUP workup. For instance, the demonstration of mucin (mucicarmine stain) indicates a likely adenocarcinoma, though without suggesting a site of origin. Similarly, metastatic hepatocellular carcinomas may produce pigment that can be confirmed as bile. 50 
CHROMOGENIC IN SITU HYBRIDIZATION
Nuclear probes used in place of antibodies allow for the chromogenic detection of specific nuclear sequences. In situ hybridization for human papillomavirus confirms the diagnosis of HPV-related squamous cell carcinoma, which can arise in the oropharynx, cervix, and anus. Diffuse nuclear and cytoplasmic expression of p16 by 
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IPOX is also seen in these HPV-related tumors, though some non-HPV-related tumors may diffusely express p16, making in situ hybridization the more specific test (Fig. 15) . 51 When evaluating CUP present in cervical lymph nodes, EBER testing should be considered when HPV testing is negative to exclude nasopharyngeal carcinoma, especially when the neoplasm demonstrates an undifferentiated or lymphoepithelial morphology.
MOLECULAR TESTING
Molecular testing may 1) help reveal a tumor type in instances in which IPOX is unhelpful or 2) provide clinically relevant information to guide therapy choice. The limiting factor for molecular testing in CUP workup on cytologic material is typically the limited sample size. Small biopsies do not provide enough material for a large panel of targeted molecular tests. This means that some level of suspicion must exist before a specific molecular test can be justified. For instance, a reverse-transcription polymerase chain reaction panel for EWSR1 translocation may be useful when the clinical suspicion is high for Ewing's sarcoma but the diagnosis is not supported by the IPOX results.
52
Translocations
Some entities are defined by the presence of specific translocations, in which case the presence of a translocation can confirm a diagnosis. [53] [54] [55] [56] [57] [58] For instance, midline carcinoma is characterized by the fusion of NUTM1 to another gene, typically BRD4 or BRD3. 59, 60 A partial list of translocations that may help confirm specific entities can be found in Table 7 .
Mutation Testing/Next-Generation Sequencing
Targeted mutational testing or large sequencing panels expose mutations that are associated with certain types of cancer. Unfortunately, CUP tumors are often metastatic by the time they are identified, which limits the usefulness of this approach. Metastatic tumors are expected to Figure 11 . Select additional markers used in the workup for small round blue cell tumors. Desmin may be positive in desmoplastic small round cell tumor and rhabdomyosarcoma, whereas myogenin (nuclear) is more specific for a skeletal muscle origin (rhabdomyosarcoma). Membranous CD99 staining can be seen in Ewing sarcoma; the new nuclear marker NKX2.2 (not shown) appears to have a high sensitivity (93%) for Ewing sarcoma.
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harbor a large mutational burden, which calls into question whether a specific mutation can identify a tumor's origin. Furthermore, specific mutations (eg, BRAF) are commonly found in several different tumor types and require the context of a primary site to be clinically useful. 61 In situations in which a tumor origin cannot be identified, next-generation sequencing can help identify mutations that may make a patient eligible to receive targeted therapy. It is unknown whether CUP tumors with targetable mutations are less responsive to administration of targeted therapy than tumors with known primaries; a diminished response could be due to the high mutational Figure 12 . Neuroendocrine differentiation can be determined using the markers synaptophysin and chromogranin. The newer marker INSM1 is a nuclear stain and has improved sensitivity over synaptophysin and chromogranin, but is negative in parathyroidderived cells. CD56 is positive in neuroendocrine neoplasms but is a less specific marker. Cancer Cytopathology August 2018 burden of CUP tumors that include additional unidentified mutations within the targeted pathway.
Gene Expression and MicroRNA Assays
Gene expression panels have been commercially developed to provide the probable site of origin for a given tumor. 62, 63 The accuracy likely decreases as a tumor accumulates mutations and becomes more poorly differentiated. In circumstances in which a CUP cannot be adequately identified by in-house tests such as IPOX, the identification of a likely origin through gene expression testing may be sufficient for clinical trial enrollment or to guide patient treatment. It is unclear whether these tests are more accurate than the "best guess" clinicoradiologic impression in the setting of a CUP that has eluded standard ancillary testing. In addition to gene expression arrays, microRNA-based assays have been developed that can supplement IPOX results. 64, 65 CONCLUSION IPOX remains the primary ancillary method for characterizing CUP lesions, and in certain situations molecular methods can be helpful supplements. In a patient who has widely metastatic disease, the rapid triage of residual specimen for targeted therapy testing may be more clinically relevant than pursuing an expanded IPOX panel in search of a more definitive diagnosis. Close communication between the oncology and pathology teams during a CUP workup is recommended to ensure efficient triage of a specimen and to yield the best and most clinically important information to guide patient management.
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